Supplementary Material for: Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants
Vasantha Jotwani(San Francisco VA Medical Center), For The SPRINT Research Group, Ronit Katz(University of Washington), Joachim H. Ix(University of San Diego), Mark S. Segal(Hypertension Institute), Paul E. Drawz(University of Minnesota), Alfred K. Cheung(University of Utah), Michael G. Shlipak(San Francisco VA Health Care System), Henry Punzi(Trinity Medical Center), Anthony A. Killeen(University of Minnesota), Barry I. Freedman(Wake Forest University), Jeffrey T. Bates(Michael E. DeBakey VA Medical Center), William E. Haley(Jacksonville College), Mark J. Sarnak(Tufts Medical Center), P.S. Garimella(Unknown), Michel Chonchol(University of Colorado Anschutz Medical Campus), Rakesh Malhotra
Cited by 0
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years
|JAMA|2016|1.2k
Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons
|New England Journal of Medicine|2005|1.2k